AzTrials
AzTrials

Colitis, UlcerativePhase 2ANTHEM-UCNCT06049017

A Study of JNJ-77242113 in Participants With Moderately to Severely Active Ulcerative Colitis

A Phase 2 study testing JNJ-77242113 in people with Colitis, Ulcerative, run by Janssen Research & Development, LLC at 177 sites in 21 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The purpose of this study is to evaluate the safety and effectiveness of JNJ-77242113 compared with placebo in participants with moderately to severely active ulcerative colitis. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Colitis, Ulcerative
What is being tested?
JNJ-77242113
Type of treatment
Pill or oral medicine
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
252 participants
Where
177 sitesin 21 countries
Study dates
9 Oct 2023to 5 Jan 2026
Phase
Phase 2
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Signed informed consent form 18 years of age or older
  • Documented diagnosis of ulcerative colitis (UC) of at least 12 weeks prior to screening
  • Moderately to severely active UC as per the modified Mayo score
  • Demonstrated inadequate response to or intolerance of conventional therapy and/or advanced therapy as defined in the protocol

Who cannot join

  • Participants with current or prior diagnosis of fulminant colitis and/or toxic megacolon
  • UC limited to rectum only or to less than (<) 15 centimeters (cm) of colon
  • Presence of a stoma
  • Presence or history of fistula
  • History of extensive colonic resection (example, <30 cm of colon remaining)
  • Diagnosis of indeterminate colitis, microscopic colitis, ischemic colitis, Crohn's colitis or clinical findings suggestive of Crohn's disease

Trial locations and contacts

177 sites in 21 countries.

177 sites in 21 countries

United States32 sites

  • Clinnova Research

    Anaheim, California, 92805

  • Atlanta Gastroenterology Associates

    Atlanta, Georgia, 30342

  • Mercy Medical Center

    Baltimore, Maryland, 21202-2102

  • Washington Gastroenterology, PLLC

    Bellevue, Washington, 98004

  • UNC Hospitals

    Chapel Hill, North Carolina, 27514

  • Atrium Health

    Charlotte, North Carolina, 28204

  • Charlotte Gastroenterology and Hepatology, PLLC

    Charlotte, North Carolina, 28207

  • Gastroenterology Associates of Tidewater

    Chesapeake, Virginia, 23320

  • Peak Gastroenterology Associates

    Colorado Springs, Colorado, 80907

  • DHAT Research Institute

    Garland, Texas, 75044

  • Amel Med LLC Research

    Georgetown, Texas, 78628

  • Gastroenterology Associates P.A.

    Greenville, South Carolina, 29607

  • Accurate Clinical Research, Inc.

    Humble, Texas, 77346

  • Ochsner Medical Center

    Jefferson, Louisiana, 70121

  • I.H.S. Health. LLC

    Kissimmee, Florida, 34741

  • Caprock Gastro Research

    Lubbock, Texas, 79424

  • Tandem Clinical Research

    Marrero, Louisiana, 70072

  • Gastroenterology of Southern Indiana

    New Albany, Indiana, 47150

  • New York Gastroenterology Associates

    New York, New York, 10075

  • Hoag Memorial Hospital

    Newport Beach, California, 92663

  • DiGiovanna Institute for Medical Education & Research

    North Massapequa, New York, 11758

  • Care Access Research, Ogden

    Ogden, Utah, 84403

  • Digestive Disease Specialists Inc

    Oklahoma City, Oklahoma, 73112

  • Endoscopic Research Inc

    Orlando, Florida, 32803-1853

  • Mayo Clinic Rochester

    Rochester, Minnesota, 55905

  • Southern Star Research Institute, LLC

    San Antonio, Texas, 78229

  • Medical Associates Research Group, Inc.

    San Diego, California, 92123

  • Washington Gastroenterology, PLLC 1

    Tacoma, Washington, 98405

  • GCP Clinical Research

    Tampa, Florida, 33609

  • Cotton O'Neil Digestive Health Center

    Topeka, Kansas, 66606

  • Tyler Research Institute, LLC

    Tyler, Texas, 75701

  • Northshore Gastroenterology Research, LLC

    Westlake, Ohio, 44145

Other trials in United States

Japan14 sites

  • Sai Gastroenterology Proctology

    Fujiidera-shi, 583-0027

  • Hamamatsu University Hospital

    Hamamatsu, 431 3192

  • Kagoshima IBD Gastroenterology Clinic

    Kagoshima, 892-0843

  • Tsujinaka Hospital Kashiwanoha

    Kashiwa, 277-0871

  • Aoyama Naika Clinic

    Kobe, 650-0015

  • Kinshukai Infusion Clinic

    Osaka, 530-0011

  • Japanese Red Cross Osaka Hospital

    Osaka, 543 8555

  • Toho University Sakura Medical Center

    Sakura, 285-8741

  • Sapporo Tokushukai Hospital

    Sapporo, 004-0041

  • Sapporo Higashi Tokushukai Hospital

    Sapporo, 065-0033

  • National Hospital Organization Shizuoka Medical Center

    Shimizu, 411-8611

  • Tokyo Metropolitan Bokutoh Hospital

    Sumida Ku, 130 8575

  • Mie University Hospital

    Tsu, 514 8507

  • Yokohama City University Medical Center

    Yokohama, 232 0024

Other trials in Japan

China12 sites

  • The second Xiangya Hospital of Central South University

    Changsha, 410011

  • Chongqing General Hospital

    Chongqing, 400014

  • The First Affiliated Hospital Sun Yat sen University

    Guangzhou, 510060

  • The Sixth Affiliated Hospital Sun Yat sen University

    Guangzhou, 510655

  • Sir Run Run Shaw Hospital Zhejiang University School of Medicine

    Hangzhou, 310000

  • Qilu Hospital of Shandong University

    Jinan, 250012

  • Lanzhou University Second Hospital

    Lanzhou, 730031

  • Nanjing Drum Tower Hospital

    Nanjing, 210008

  • Shengjing Hospital Of China Medical University

    Shenyang, 110022

  • Union Hospital Tongji Medical College of Huazhong University of Science and Technology

    Wuhan, 430022

  • Wuxi People s Hospital

    Wuxi, 214023

  • The Second Affiliated Hospital of Air Force Medical University - Tangdu Hospital

    Xi'an, 710038

Other trials in China

Poland12 sites

  • Centrum Medyczne Medis ManerMed Sp Z O O

    Bydgoszcz, 85 229

  • Centrum Medyczne Lukamed Spolka z Ograniczona Odpowiedzialnoscia

    Chojnice, 89-600

  • Centrum Medyczne Plejady

    Krakow, 30 363

  • Centrum Medyczne Medyk

    Rzeszów, 35-326

  • Sonomed Sp. z o.o.

    Szczecin, 71-685

  • GASTROMED Sp. z o.o.

    Torun, 87 100

  • Centralny Szpital Kliniczny Mswia

    Warsaw, 02 507

  • Bodyclinic Sp. z o.o. sp. k

    Warsaw, 03 712

  • Medical Network Spolka z o.o. WIP Warsaw IBD Point Profesor Kierkus

    Warsaw, 04 501

  • Centrum Medyczne Oporow

    Wroclaw, 52 416

  • Melita Medical Sp. z o.o.

    Wroclaw, 53 611

  • EMC Instytut Medyczny SA

    Wroclaw, 54 144

Other trials in Poland

France11 sites

  • CHRU Besancon Hopital Jean Minjoz

    Besançon, 25030

  • APHP - Hopital Henri Mondor

    Créteil, 94000

  • CHRU de Lille Hopital Claude Huriez

    Lille, 59037

  • Clinique Ambroise Pare

    Neuilly-sur-Seine, 92200

  • CHU de Nice Hopital de l Archet

    Nice, 06202

  • CHU Nimes Hopital Caremeau

    Nîmes, 30900

  • APHP - Hopital Bichat - Claude Bernard

    Paris, 75018

  • Hospices Civils de Lyon CHU Lyon Sud

    Pierre-Bénite, 69495

  • CHU Saint Etienne Hopital Nord

    Saint-Priest-en-Jarez, 42270

  • CHU Toulouse - Hopital de Rangueil

    Toulouse, 31400

  • CHU de Nancy_ Hopital Brabois

    Vandœuvre-lès-Nancy, 54500

Other trials in France

Spain11 sites

  • Hosp. Univ. Fundacion Alcorcon

    Alcorcón, 28922

  • Hosp. Arquitecto Marcide

    Ferrol, 15405

  • Hosp. de Cabuenes

    Gijón, 33394

  • Hosp. Univ. La Paz

    Madrid, 28046

  • Hosp. Univ. Pta. de Hierro Majadahonda

    Majadahonda, 28222

  • Hosp. Clinico Univ. de Santiago

    Santiago de Compostela, 15706

  • Hosp. Virgen Macarena

    Seville, 41009

  • Hosp. Ntra. Sra. de Valme

    Seville, 41014

  • Hosp. Clinico Univ. de Valencia

    Valencia, 46010

  • Hosp. Univ. I Politecni La Fe

    Valencia, 46026

  • Hosp. Alvaro Cunqueiro

    Vigo, 36312

Other trials in Spain

United Kingdom9 sites

  • Fairfield General Hospital

    Bury, Greater Manchester

  • Addenbrookes Hospital

    Cambridge, CB2 0QQ

  • Barts Health NHS Trust

    London, E11 1NR

  • Guys St Thomas Hospital

    London, SE1 7EH

  • Kings College Hospital

    London, SE5 9RS

  • St Georges University Hospital NHS Foundation Trust

    London, SW17 0RE

  • Oxford University Hospitals NHS Foundation Trust

    Oxford, OX3 9DU

  • Whiston Hospital

    Prescot, L35 5DR

  • Southampton University Hospital

    Southampton, SO16 6YD

Other trials in United Kingdom

Brazil8 sites

  • UNESP - Faculdade de Medicina da Universidade Estadual Paulista - Campus Botucatu

    Botucatu, 18618-687

  • L2IP Instituto de Pesquisas Clinicas

    Brasília, 70.200-730

  • CDC - Centro Digestivo de Curitiba

    Curitiba, 80430-180

  • Hospital de Clinicas de Porto Alegre - Hospital de Clinicas

    Porto Alegre, 90035 903

  • Pesquisare Saude

    Santo André, 09080-110

  • BR TRIALS Ensaios Clinicos e Consultoria Ltda

    São Paulo, 01236030

  • Instituto D Or de Pesquisa e Ensino

    São Paulo, 01401 002

  • INTEGRAL Pesquisa e Ensino

    Votuporanga, 15501-405

Other trials in Brazil

Germany8 sites

  • Klinikum Augsburg

    Augsburg, D-86158

  • Krankenhaus Waldfriede Mitte

    Berlin, 14163

  • Universitaetsklinikum Carl Gustav Carus TU Dresden

    Dresden, 01307

  • Medizinische Hochschule Hannover

    Hanover, 30625

  • Universitatsklinikum Schleswig Holstein Kiel

    Kiel, 24105

  • Eugastro GmbH

    Leipzig, 04103

  • Staedtisches Klinikum Lueneburg

    Lüneburg, 21339

  • Gastroenterologische Gemeinschaftspraxis Minden

    Minden, 32423

Other trials in Germany

Italy7 sites

  • Fondazione IRCCS Ca Granda Ospedale Policlinico Di Milano

    Milan, 20122

  • Ospedale San Raffaele di Milano

    Milan, 20132

  • Ospedale Sacro Cuore Don Calabria

    Negrar, 37024

  • Azienda Ospedaliera San Camillo - Roma

    Roma, 00152

  • Fondazione Policlinico Universitario A Gemelli IRCCS

    Roma, 00168

  • Istituto Clinico Humanitas

    Rozzano, 20089

  • Casa Sollievo Della Sofferenza IRCCS

    San Giovanni Rotondo, 71013

Other trials in Italy

South Korea7 sites

  • Inje University Haeundae Paik Hospital

    Busan, 48108

  • Yeungnam University Hospital

    Daegu, 42415

  • Seoul National University Hospital

    Seoul, 03080

  • Kangbuk Samsung Hospital

    Seoul, 03181

  • Asan Medical Center

    Seoul, 05505

  • Samsung Medical Center

    Seoul, 06351

  • The Catholic university of Korea, St. Vincent's Hospital

    Suwon, 16247

Other trials in South Korea

Belgium6 sites

  • CHU Saint-Pierre

    Brussels, 1000

  • AZ Sint-Lucas

    Ghent, 9000

  • Ghent University Hospital

    Ghent, 9000

  • Universitair Ziekenhuis Leuven

    Leuven, 3000

  • Centre Hospitalier Universitaire de Liege Domaine Universitaire du Sart Tilman

    Liège, 4000

  • Vitaz

    Sint-Niklaas, 9100

Other trials in Belgium

Hungary6 sites

  • Semmelweis Egyetem

    Budapest, 1083

  • Semmelweis Egyetem 1

    Budapest, 1088

  • Pannónia Magánorvosi Centrum Kft

    Budapest, H-1136

  • Vasutegeszsegugyi Nonprofit Kozhasznu Kft

    Debrecen, 4025

  • Debreceni Egyetem Gasztroenterologiai Klinika

    Debrecen, 4032

  • Clinexpert Kft

    Gyöngyös, 3200

Other trials in Hungary

Argentina5 sites

  • Cer Instituto Medico

    Buenos Aires, B1878DVB

  • CIPREC

    Buenos Aires, C1061AAS

  • Gedyt - Consultorios Gastroenterologia

    Buenos Aires, C1425

  • Hospital Provincial del Centenario

    Rosario, S2000KDS

  • Sanatorio 9 de Julio

    San Miguel de Tucumán, 4000

Other trials in Argentina

Canada5 sites

  • Barrie GI Associates

    Barrie, Ontario, L4M 7G1

  • Gastroenterology and Internal Medicine Research Institute (GIRI)

    Edmonton, Alberta, T5R 1W2

  • London Health Sciences Centre

    London, Ontario, N6A 5A5

  • Centre Hospitalier de l'Universite de Montreal

    Montreal, Quebec, H2X 0C1

  • ABP Research Services Corp.

    Oakville, Ontario, L6L 5L7

Other trials in Canada

Czechia5 sites

  • Nemocnice Ceske Budejovice

    České Budějovice, 370 01

  • Gastroenterologie, s.r.o., Hradec Kralove

    Hradec Kralova, 500 02

  • Hepato-gastroenterologie HK, s.r.o.

    Hradec Králové, 500 12

  • ISCARE a.s.

    Prague, 19000

  • Nemocnice Slany

    Slaný, 27401

Other trials in Czechia

Australia4 sites

  • Sunshine Coast University Hospital

    Birtinya, 4575

  • Blacktown Hospital

    Blacktown, 2148

  • Concord Repatriation General Hospital

    Concord, 2139

  • Wollongong Private Hospital

    Wollongong, 2500

Other trials in Australia

India4 sites

  • S. R. Kalla Memorial General Hospital

    Jaipur, 302006

  • Midas Hospital

    Nagpur, 441108

  • Govind Ballabh Pant Hospital

    New Delhi, 110002

  • SIDS Hospital & Research Centre

    Surat, 395002

Other trials in India

Romania4 sites

  • Spital Memorial

    Bucharest, 013823

  • S C Delta Health Care S R L

    Bucharest, 014146

  • Digenio - Centrul Medical de Gastroenterologie, Hepatologie si Endoscopie Digestiva

    Cluj-Napoca, 400061

  • Centrul Medical Valahia

    Ploieşti, 100032

Other trials in Romania

Turkey (Türkiye)4 sites

  • Gazi University Medical Faculty

    Ankara, 6500

  • Uludag Universitesi Tıp Fakultesi Hastanesi

    Bursa, 16059

  • Ege Universitesi Tip Fakultesi

    Izmir, 35040

  • Mersin University Medical Faculty

    Mersin, 33343

Other trials in Turkey (Türkiye)

Malaysia3 sites

  • Hospital Sultanah Aminah

    Johor Bahru, 80100

  • Sultan Idris Shah Hospital

    Kajang, 43000

  • University Malaya Medical Centre

    Kuala Lumpur, 59100

Other trials in Malaysia

About this study

Official title: A Phase 2b Multicenter, Randomized, Placebo- Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Moderately to Severely Active Ulcerative Colitis

The purpose of this study is to evaluate the safety and effectiveness of JNJ-77242113 compared with placebo in participants with moderately to severely active ulcerative colitis.

Being tested
JNJ-77242113, Placebo
Medical subject headings
Colitis, Ulcerative

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • JNJ-77242113Drug

    JNJ-77242113 tablet will be administered orally.

  • PlaceboDrug

    Placebo tablet will be administered orally.

Study groups in NCT06049017
Study groupRoleWhat they receive
Group 1: JNJ-77242113 Dose-1ExperimentalParticipants will receive JNJ-77242113 Dose-1 tablets orally from Week 0 through Week 28. Participants who complete the Week 28 assessments and have achieved clinical response at Week 28 and who, in the opinion of the investigator, will continue to benefit from treatment with study intervention will continue in the 48-week long term extension (LTE) period and receive the same treatment up to Week 76.
Receives: Drug: JNJ-77242113
Group 2: JNJ-77242113 Dose-2ExperimentalParticipants will receive JNJ-77242113 Dose-2 tablets orally from Week 0 through Week 28. Participants who complete the Week 28 assessments and have achieved clinical response at Week 28 and who, in the opinion of the investigator, will continue to benefit from treatment with study intervention will continue in the 48-week LTE period and receive the same treatment up to Week 76.
Receives: Drug: JNJ-77242113
Group 3: JNJ-77242113 Dose-3ExperimentalParticipants will receive JNJ-77242113 Dose-3 tablets orally from Week 0 through Week 28. Participants who complete the Week 28 assessments and have achieved clinical response at Week 28 and who, in the opinion of the investigator, will continue to benefit from treatment with study intervention will continue in the 48-week LTE period and receive the same treatment up to Week 76.
Receives: Drug: JNJ-77242113
Group 4: PlaceboExperimentalParticipants will receive placebo tablets orally from Week 0 through Week 28. Placebo-treated participants who meet the criteria of inadequate response at Week 16, will receive JNJ-77242113 Dose-3 tablet orally through Week 28. Participants who complete the Week 28 assessments and have achieved clinical response at Week 28 and who, in the opinion of the investigator, will continue to benefit from treatment with study intervention, will continue in the 48-week LTE period and receive the same treatment up to Week 76.
Receives: Drug: JNJ-77242113; Drug: Placebo

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Percentage of Participants with Clinical Response at Week 12

    Clinical response is defined as decrease from baseline in the modified Mayo score by greater than or equal to (>=) 30 percent (%) and >=2 points, with either a >=1-point decrease from baseline in the rectal bleeding subscore or a rectal bleeding subscore of 0 or 1.

    Measured: Week 12

Secondary outcomes (5)

  1. Percentage of Participants with Clinical Remission at Week 12

    Clinical remission is defined as stool frequency subscore of 0 or 1, where the stool frequency subscore has not increased from baseline, a rectal bleeding subscore of 0, and an endoscopy subscore of 0 or 1.

    Measured: Week 12

  2. Percentage of Participants with Symptomatic Remission at Week 12

    Symptomatic remission is defined as stool frequency subscore of 0 or 1, where the stool frequency subscore has not increased from baseline, and a rectal bleeding subscore of 0.

    Measured: Week 12

  3. Percentage of Participants with Endoscopic Improvement at Week 12

    Endoscopic improvement is defined as an endoscopy subscore of 0 or 1.

    Measured: Week 12

  4. Percentage of Participants with Histologic-endoscopic Mucosal Improvement at Week 12

    Histologic-endoscopic mucosal improvement is defined as a combination of histologic remission and endoscopic improvement. Histologic remission and endoscopic improvement are based on the histologic grading and the Mayo endoscopy subscore.

    Measured: Week 12

  5. Percentage of Participants with Adverse Events (AE) and Serious Adverse Evets (SAEs)

    An AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. A SAE is any untoward medical occurrence that at any dose: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; is a suspected transmission of any infectious agent via a medicinal product; is medically important.

    Measured: Up to Week 76

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted21 Sep 2023
  2. Study start9 Oct 2023
  3. Primary completion26 Sep 2024
  4. Study completion5 Jan 2026

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Double blind
Who is masked
Participant, Investigator
Enrolment
252 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06049017
Sponsor's protocol ID
77242113UCO2001
Other IDs
77242113UCO2001, 2023-504673-20-00, 2023
Acronym
ANTHEM-UC
Status last verified
Apr 2026
First submitted
15 Sep 2023
Last updated
13 Apr 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
Yes: The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \& Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

Publications

  • Abreu MT, Siegmund B, Surace L, Erondu N, Chen M, Chachu K, Louis E, Matsuoka K, Limdi J, Arthur E, Houck N, Marano C, Vetter ML, Zou B, Zhan J, Frustaci ME, Kannan AK, Rydzewska G, Loftus EV Jr, Jairath V; ANTHEM-UC Study Group. Phase 2 Trial of Icotrokinra for Patients with Ulcerative Colitis. N Engl J Med. 2026 Oct 15;395(15):1495-1504. doi: 10.1056/NEJMoa2604435.

    PubMed 42874103

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing JNJ-77242113 in people with Colitis, Ulcerative, run by Janssen Research & Development, LLC at 177 sites in 21 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 13 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 177 sites in United States, Japan, China, Poland, France and 16 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Percentage of Participants with Clinical Response at Week 12 (time frame: Week 12). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06049017, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Apr 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in